Management of Cancer Therapy Related Vulvovaginal Atrophy
Genitourinary Syndrome of Menopause
About this trial
This is an interventional treatment trial for Genitourinary Syndrome of Menopause
Eligibility Criteria
Inclusion Criteria: Patients have symptoms of VVA (vaginal dryness, burning, itching or dyspareunia) Patients with vaginal health index < 15. All patients have already finished cancer therapy or are on anti-estrogen treatment. Married sexually active Patients who are not receiving any VVA treatment for at least 30 days before starting therapy. Exclusion Criteria: Active or recent history of vulvovaginal inflammation or infection History of vulvar or vaginal cancer. Suspicious lesion in the vulvovaginal area on the gynecological examination
Sites / Locations
- Alexandria University
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Active Comparator
Active Comparator
PRP- treated Group A
PRP-HA treated Group B
Control Group C
15 female patients will receive 2 vaginal PRP injections one month apart.
15 female patients will receive 2 vaginal PRP-non-cross-linked HA injections spaced a month apart.
15 female patients will receive topical non-cross-linked hyaluronic acid gel applied every three days for 2 months as a control group